Preserving Our Hometown Independent Pharmacies Act of 2011

Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issue relating to proposed anti-trust exemption for certain pharmacies and healthcare competition HR 1409 - Quality Health Care Coalition Act of 2011 HR 1839 - Community Pharmacy Fairness Act of 2011 HR 1946 - Preserving Our Hometown Independent Pharmacies Act

Client expense: $2,930,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 605 / S. 312 -All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 -All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs 340b program H.R. 2672 the Preserving Access to Orphan Drugs Act H.R. 2182 the Generating Antibiotic Incentives Now Act H.R. 3026 the Safeguarding Americas Pharmaceuticals Act H.R. 2746 the Cancer Drug Coverage Parity Act H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act

Client expense: $559,998 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

H.R. 5: All provisions of the Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011; H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733: All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 4 /S.18 / S.72 - All provisions of the Small Business Paperwork Mandate Elimination Act H.R. 605 / S. 312 - All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 - All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs Regulatory Implementation of the HITECH Act FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs), implementation of approval pathway for generic biologic drugs 340b program H.R. 2245/S. 296 - All provisions of the Preserving Access to Life-Saving Medications Act of 2011

Client expense: $559,998 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

H.R. 1839, Community Pharmacy Fairness Act of 2011 H.R. 1946, Preserving Our Hometown Independent Pharmacies Act of 2011 S. 1058, Pharmacy Competition and Consumer Choice Act of 2011

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs, H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) - antitrust exemption for independent pharmacies, H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) - pay-for-delay settlements, S. 27, Preserve Access to Affordable Generics Act (Kohl) - pay-for-delay settlements, S. 2002, Online Pharmacy Safety Act (Feinstein) - establishes standards for on-line pharmacies, S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) - FDA oversight of medical devices, S. 3187, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs 16. Specific Lobbying Issues (continued): H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2002, Online Pharmacy Safety Act (Feinstein) establishes standards for on-line pharmacies S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices S. 3187, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.

Client expense: $2,020,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office

Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).

Client expense: $630,728 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office

Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Medical Loss Ratio.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issue relating to proposed anti-trust exemption for certain pharmacies and healthcare competition HR 1409 - Quality Health Care Coalition Act of 2011 HR 1839 - Community Pharmacy Fairness Act of 2011 HR 1946 - Preserving Our Hometown Independent Pharmacies Act

Client expense: $2,930,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Health Care Reform regulatory implementation and compliance issues from the Patient Protection and Affordable Care Act (PPACA) Public Law No: 111-148 & the Health Care and Education Reconciliation Act of 2010 (HCERA) Public Law No: 111-152 Health Flexible Spending Arrangements Improvements Act of 2012 H.R. 1004 Medicare Beneficiary Freedom to Choose Act of 2011 H.R. 1051 Preserving our Hometown Independent Pharmacies Act of 2011 H.R. 1946 Family and Retirement Health Investment Act of 2011 H.R. 2010 Tax Parity for Health Plan Beneficiaries Act of 2011 H.R. 2088/S. 1171 Restoring Access to Medication Act of 2012 H.R. 2529/5842 Health Savings Accounts Improvements Act of 2012 H.R. 5858 Empowering States to Innovate Act S. 248 Patients Freedom to Choose Act S. 312 Family and Retirement Health Investment Act S. 1098 Other Issues Health care provider compensation Internal Revenue Code Section 162 (m) (6) Electronic disclosure, communication by employee benefit plans Consumer directed health care plans HDHPs, HSAs, HRAs FSA Plan Year Limit transition guidance Mental Health Parity Rules

Client expense: $328,952 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commodity Futures Trading Commission (CFTC), Equal Employment Opportunity Commission (EEOC), Federal Accounting Standards Advisory Board (FASAB), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, White House Office

S.1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; SEE ADDENDUM S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S.319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in the National Defense Authorization Act for FY2013; Medicare Part B Revalidation; Hydrocodone Issues; S. 3376, PACT Act, S. 2467 and S. 3254 and H.R. 4310, he National Defense Authorization Act for FY2013; S. 3604, Improving Dementia Care Treatment for Older Adults Act of 2012; Deficit Reduction Issues

Client expense: $320,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE

Issues relating to a proposed anti-trust exemption for certain pharmacies. H.R.1409, Quality Health Care Coalition Act of 2011; H.R.1839, Community Pharmacy Fairness Act of 2011; H.R.1946, Preserving our Hometown Independent Pharmacies Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

P.L. 112-25 - The Budget Control Act of 2011. Focused on changes that could impact Medicare, Medicaid and the private market with regard to prescription drug benefits. H.R. 1946 Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies. Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions. Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits. S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies. Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order. Issues related to the practice of providing coupons for prescription medications for seniors. H.R. 8- American Taxpayer Relief Act of 2012 - Issues related to PMBs in the context of Medicare and Medicaid H.R. 4310 - National Defense Authorization Act for 2013 - Issues related to the utilization of mail order pharmacy for Tricare beneficiaries.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies. Issues related to the practice of giving coupons for certain prescription medications. S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies. H.R. 4310 - National Defense Authorization Act for 2013 - Issues related to the utilization of mail order pharmacy for Tricare beneficiaries.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which creates and antitrust exemption for certain pharmacies. Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy. Issues impacting PBMs included in the Prescription Drug User Fee Act reauthorization and the Generic Drug User Fee Reauthorization. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Changes in International Naming policies for generic medications.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 1946, to allow independent pharmacists to negotiate with PBMs by exempting them from antitrust laws

Client expense: Not reported · Firm income: $45,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 605 / S. 312 -All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 -All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs 340b program H.R. 2672 the Preserving Access to Orphan Drugs Act H.R. 2182 the Generating Antibiotic Incentives Now Act H.R. 3026 the Safeguarding Americas Pharmaceuticals Act H.R. 2746 the Cancer Drug Coverage Parity Act H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act

Client expense: $518,430 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

H.R. 5: All provisions of the Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011; H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733: All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 4 /S.18 / S.72 - All provisions of the Small Business Paperwork Mandate Elimination Act H.R. 605 / S. 312 - All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 - All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs Regulatory Implementation of the HITECH Act FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs), implementation of approval pathway for generic biologic drugs 340b program H.R. 2245/S. 296 - All provisions of the Preserving Access to Life-Saving Medications Act of 2011

Client expense: $518,430 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE

H.R. 1839, Community Pharmacy Fairness Act of 2011 H.R. 1946, Preserving Our Hometown Independent Pharmacies Act of 2011 S. 1058, Pharmacy Competition and Consumer Choice Act of 2011

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs. H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) - antitrust exemption for independent pharmacies. H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) - pay-for-delay settlements. S. 27, Preserve Access to Affordable Generics Act (Kohl) - pay-for-delay settlements. S. 2002, Online Pharmacy Safety Act (Feinstein) - establishes standards for on-line pharmacies. S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) - FDA oversight of medical devices. S. 3187, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1409, HR 1946, HR 1839).

Client expense: $423,292 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, White House Office

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs 16. Specific Lobbying Issues (continued): H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2002, Online Pharmacy Safety Act (Feinstein) establishes standards for on-line pharmacies S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices S. 3187, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to access for investigational drugs; and other issues relating to health care reform implementation.

Client expense: $2,630,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office

Issues relating to a proposed anti-trust exemption for certain pharmacies, healthcare competition and the CVS Caremark business model. H.R.1409, Quality Health Care Coalition Act of 2011; H.R.1839, Community Pharmacy Fairness Act of 2011; H.R.1946, Preserving our Hometown Independent Pharmacies Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Patients Freedom to Choose Act H.R. 605 Health Flexible Spending Arrangements Improvements Act of 2012 H.R. 1004 Medicare Beneficiary Freedom to Choose Act of 2011 H.R. 1051 Preserving our Hometown Independent Pharmacies Act of 2011 H.R. 1946 Family and Retirement Health Investment Act of 2011 H.R. 2010 Tax Parity for Health Plan Beneficiaries Act of 2011 H.R. 2088 Restoring Access to Medication Act of 2012 H.R. 2529/5842 Health Savings Accounts Improvements Act of 2012 H.R. 5858 Health Care Reform regulatory implementation and compliance issues from the Patient Protection and Affordable Care Act (PPACA) Public Law No: 111-148 & the Health Care and Education Reconciliation Act of 2010 (HCERA) Public Law No: 111-152 Senate State Leadership in Health Act S. 73 State Health Care Choice Act S. 244 Empowering States to Innovate Act S. 248 Patients Freedom to Choose Act S. 312 Family and Retirement Health Investment Act S. 1098 Tax Parity for Health Plan Beneficiaries Act of 2011 S. 1171 Restoring Access to Medication Act S. 1368 Health Care Reform regulatory implementation and compliance issues from the Patient Protection and Affordable Care Act (PPACA) Public Law No: 111-148 & the Health Care and Education Reconciliation Act of 2010 (HCERA) Public Law 111-152 Regulatory Proposed Health Information Technology for Economic and Clinical Health (HITECH) Act regulations for HIPAA Accounting of Disclosures Request for Information (RFI) streamlining regulations to reduce regulatory burdens - Improving Regulation and Regulatory Review Executive Order 13563 Semi-Annual Regulatory Agendas HHS, Treasury Guidance for and implementation of the Patient Protection and Affordable Care Act (PPACA) & the Health Care and Education Reconciliation Act of 2010 (HCERA) Frequently Asked Questions (FAQs), employer responsibility provisions (shared responsibility, pay to play), quality improvement efforts, Essential Health Benefits (EHB), W2 informational reporting, Summary of Benefits and Coverage Requirements & uniform glossary requirements, automatic enrollment, waiting periods, medical loss ratios (MLRs), contraceptive coverage, state waivers, state health exchanges, reinsurance assessment, public reporting and accountability related to hospital patient safety measures, Patient-Centered Outcomes Research Institute (PCORI), request for transition relief for health flexible spending arrangements (health FSAs) in non-calendar years, Health Insurance Premium Tax Credit, minimum value of an employer sponsored health plan, health insurance premium tax credit/effect of wellness incentive programs, definition of Full-Time Employee, 90-Day waiting period Medicare and Medicaid Programs; Electronic Health Record Incentive Program Stage 2, Health IT Meaningful Use project Health care provider compensation Internal Revenue Code Section 162 (m) (6) Electronic disclosure, communication by employee benefit plans Consumer directed health care plans HDHPs, HSAs, HRAs FSA Plan Year Limit transition guidance Mental Health Parity Rules

Client expense: $216,050 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commodity Futures Trading Commission (CFTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, White House Office

Implementation of the Patient Protection and Affordability Act (P.L. 111-148): Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Medical Loss Ratio.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issue relating to proposed anti-trust exemption for certain pharmacies and healthcare competition HR 1409 - Quality Health Care Coalition Act of 2011 HR 1839 - Community Pharmacy Fairness Act of 2011 HR 1946 - Preserving Our Hometown Independent Pharmacies Act

Client expense: $2,320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Competition and antitrust legislation issues. HR 1946, to allow independent pharmacists to negotiate with Pharmacy Benefit Managers by exempting them from antitrust laws.

Client expense: Not reported · Firm income: $45,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

P.L. 112-25 - The Budget Control Act of 2011. Focused on changes that could impact Medicare, Medicaid and the private market with regard to prescription drug benefits. H.R. 1946 Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies. Work focused on Health Reform Law-related regulations specific to Essential Health Benefits provisions. Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits. S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies. Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order. Issues related to the practice of providing coupons for prescription medications for seniors.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies. Issues related to the practice of giving coupons for certain prescription medications. S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation; Hydrocodone Issues; S. 3376, PACT Act, S. 2467 and S. 3254 and H.R. 4310, the National Defense Authorization Act for Fiscal Year 2013; S. 3604, Improving Dementia Care Treatment for Older Adults Act of 2012;

Client expense: $300,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE

H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which creates and antitrust exemption for certain pharmacies. Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy. Issues impacting PBMs included in the Prescription Drug User Fee Act reauthorization and the Generic Drug User Fee Reauthorization. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 1946, to allow independent pharmacists to negotiate with Pharmacy Benefit Managers by exempting them from antitrust laws.

Client expense: Not reported · Firm income: $45,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1839, Community Pharmacy Fairness Act of 2011 H.R. 1946, Preserving Our Hometown Independent Pharmacies Act of 2011 S. 1058, Pharmacy Competition and Consumer Choice Act of 2011

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to a proposed anti-trust exemption for certain pharmacies, healthcare competition and the CVS Caremark business model; H.R. 1409, Quality Health Care Coalition Act of 2011; H.R. 1839, Community Pharmacy Fairness Act of 2011; H.R. 1946, Preserving our Hometown Independent Pharmacies Act.

Client expense: Not reported · Firm income: $20,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) FEHBP prescription drugs H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) antitrust exemption for independent pharmacies H.R. 3988, Generic Drug and Biosimilar User Fee Act (Murphy/Pitts/Waxman) FDA user fee programs 16. Specific Lobbying Issues (continued): H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) pay-for-delay settlements H.R. 5651, FDA Reform Act (Upton) pharmaceutical, medical device issues S. 27, Preserve Access to Affordable Generics Act (Kohl) pay-for-delay settlements S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) FDA oversight of medical devices S. 2516, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues S. 3187, the FDA Safety and Innovation Act (Harkin) pharmaceutical, medical device issues S. 2002, Online Pharmacy Safety Act (Feinstein) establishes standards for on-line pharmacies Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs; and other issues relating to health care reform implementation.

Client expense: $2,240,000 · Firm income: Not reported

Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Office of Personnel Management (OPM), Pension & Welfare Benefits Administration, SENATE, Treasury, Dept of, White House Office

Issues relating to a proposed anti-trust exemption for certain pharmacies and healthcare competition. HR 1409 Quality Health Care Coalition Act of 2011 HR 1839 - Community Pharmacy Fairness Act of 2011 HR 1946 - Preserving Our Hometown Independent Pharmacies Act

Client expense: $2,255,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Patient Protection and Affordability Act (P.L. 111-149); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; S. 1058/H.R. 1971, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Medical Loss Ration.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1893 and HR 1946 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate terms and conditions with health plans and pharamcy benefit managers.

Client expense: $150,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (Lynch) - FEHBP prescription drugs H.R.1946, Preserving Hometown Independent Pharmacies Act (Marino) - antitrust exemption for independent pharmacies H.R. 3988, Generic Drug and Biosimilar User Fee Act (Murphy/Pitts/Waxman) - FDA user fee programs H.R. 3995, Protecting Consumer Access to Generic Drugs Act (Rush) - pay-for-delay settlements H.R. 5651, FDA Reform Act (Upton) - pharmaceutical, medical device issues S. 27, Preserve Access to Affordable Generics Act (Kohl) - pay-for-delay settlements S. 2193, Ensuring Safe Medical Devices for Patients (Merkley) - FDA oversight of medical devices S. 2516, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues S. 3187, the FDA Safety and Innovation Act (Harkin) - pharmaceutical, medical device issues S. 2002, Online Pharmacy Safety Act (Feinstein) - establishes standards for on-line pharmacies

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patients Freedom to Choose Act H.R. 605 Health Flexible Spending Arrangements Improvements Act of 2012 H.R. 1004 Medicare Beneficiary Freedom to Choose Act of 2011 H.R. 1051 Preserving our Hometown Independent Pharmacies Act of 2011 H.R. 1946 Family and Retirement Health Investment Act of 2011 H.R. 2010 Tax Parity for Health Plan Beneficiaries Act of 2011 H.R. 2088 Restoring Access to Medication Act of 2012 H.R. 2529/5842 Health Savings Accounts Improvements Act of 2012 H.R. 5858 Health Care Reform regulatory implementation and compliance issues from the Patient Protection and Affordable Care Act (PPACA) Public Law No: 111-148 & the Health Care and Education Reconciliation Act of 2010 (HCERA) Public Law No: 111-152 Fiscal Year 2012 & 2012 Budget Proposals budgetary impacts of health entitlement programs Joint Select Committee on Deficit Reduction impact on employee benefits provisions Senate State Leadership in Health Act S. 73 State Health Care Choice Act S. 244 Empowering States to Innovate Act S. 248 Patients Freedom to Choose Act S. 312 Family and Retirement Health Investment Act S. 1098 Tax Parity for Health Plan Beneficiaries Act of 2011 S. 1171 Restoring Access to Medication Act S. 1368 Health Care Reform regulatory implementation and compliance issues from the Patient Protection and Affordable Care Act (PPACA) Public Law No: 111-148 & the Health Care and Education Reconciliation Act of 2010 (HCERA) Public Law 111-152 Fiscal Year 2012 & 2013 Budget Proposals budgetary impacts of health, health care reform and retirement entitlement programs Joint Select Committee on Deficit Reduction impact on employee benefits provisions Regulatory Proposed Health Information Technology for Economic and Clinical Health (HITECH) Act regulations for HIPAA Accounting of Disclosures Request for Information (RFI) streamlining regulations to reduce regulatory burdens - Improving Regulation and Regulatory Review Executive Order 13563 Semi-Annual Regulatory Agendas HHS, Treasury Guidance for and implementation of the Patient Protection and Affordable Care Act (PPACA) & the Health Care and Education Reconciliation Act of 2010 (HCERA) Frequently Asked Questions (FAQs), employer responsibility provisions (shared responsibility, pay to play), W2 informational reporting, Summary of Benefits and Coverage Requirements & uniform glossary requirements, automatic enrollment, waiting periods, medical loss ratios (MLRs), contraceptive coverage, state waivers, state health exchanges, reinsurance assessment, public reporting and accountability related to hospital patient safety measures, Patient-Centered Outcomes Research Institute (PCORI), request for transition relief for health flexible spending arrangements (health FSAs) in non-calendar years, Health Insurance Premium Tax Credit, minimum value of an employer sponsored health plan Medicare and Medicaid Programs; Electronic Health Record Incentive Program Stage 2, Health IT Meaningful Use project Health care provider compensation Internal Revenue Code Section 162 (m) (6) Electronic disclosure, communication by employee benefit plans Consumer directed health care plans HDHPs, HSAs, HRAs FSA Plan Year Limit transition guidance

Client expense: $246,648 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commodity Futures Trading Commission (CFTC), Equal Employment Opportunity Commission (EEOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of, White House Office

*FEHBP prescription drugs - HR 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act. *Pay-for-delay settlements - S 27, Preserve Access to Affordable Generics Act. *Antitrust exemption for independent pharmacies - HR 1946, Preserving Our Hometown Independent Pharmacies Act of 2011. *FDA user fee programs - HR 3988, Generic Drug and Biosimilar User Fee Act of 2012. *Pay-for-delay settlements - HR 3995, Protecting Consumer Access to Generic Drugs Act of 2012. *FDA oversight of medical devices - S 2193, Ensuring Safe Medical Devices for Patients. *Pharmaceutical, medical device issues - HR 5651, Food and Drug Administration Reform Act of 2012; S 2516, Food and Drug Administration Safety and Innovation Act; S 3187, Food and Drug Administration Safety and Innovation Act. *Standards for on-line pharmacies - S 2002, Online Pharmacy Safety Act.

Client expense: Not reported · Firm income: $100,000

Government targets: HOUSE OF REPRESENTATIVES

H.R. 1409: All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274: All provisions of the Medication Therapy Management Benefits Act of 2011; H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act H.R. 605 / S. 312 -All provisions of the Patients Freedom to Choose Act S. 27 - All provisions of the Preserve Access to Affordable Generics Act S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011 S. 44 -All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011 H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011 H.R. 1839 - All provisions of the Community Pharmacy Fairness Act of 2011; H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011; H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011 Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio) Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors Implementation of changes to the definition of Average Manufacturer Price in Medicaid Issues related to the management of Medicaid prescription drug benefits Legislation to promote generic drugs FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs 340b program H.R. 2672 the Preserving Access to Orphan Drugs Act H.R. 2182 the Generating Antibiotic Incentives Now Act H.R. 3026 the Safeguarding Americas Pharmaceuticals Act H.R. 2746 the Cancer Drug Coverage Parity Act H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act

Client expense: $520,389 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), SENATE